Design of SURPASS-IPF: A Personalized Approach to a Phase 3 Trial of Deupirfenidone Compared to Pirfenidone in Idiopathic Pulmonary Fibrosis

Publication
Written by Matthew Zola
Matthew Zola
Previous

Phase 1 Two-way Drug Interaction Study of Deupirfenidone (LYT-100) and Nintedanib in Healthy Volunteers
Next

Celea Therapeutics Will Present Phase 3 Trial Design for IPF and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress